Focus on the cutting edge, dedicated to protection.
Stay tuned for the latest updates from BIOALLY.
2025-11-10
Recently, in a laboratory at China Pharmaceutical City in Taizhou, Jiangsu Province, recombinant feline omega-interferon is undergoing pre-market stability studies, with the compilation and analysis of key data now in the final stages. Researchers are holding their breath, as this small pharmaceutical product—alongside the “Miaobeihu” feline trivalent inactivated vaccine, which was just approved here two months ago—represents not only a breakthrough from zero to one in China’s pet biopharmaceutical sector, but also signals the emergence of a formidable “Chinese force” in an industry long dominated by international giants.
Learn more
2025-10-15
On September 16, 2025, the Ministry of Agriculture and Rural Affairs issued Announcement No. 949: Recombinant feline interferon-α, independently developed by Taizhou BioAlly Biotechnology Co., Ltd., has been successfully approved for registration as a Class II new veterinary drug at the national level. This marks China’s first—and the world’s second—approved recombinant feline interferon, as well as the world’s first interferon product with dual applications: both injectable and ophthalmic. This milestone breakthrough not only signifies that China’s research and development in pet genetic engineering pharmaceuticals has entered the ranks of international leaders, but also fully demonstrates BioAlly’s outstanding capacity for technological innovation. Committed to independent R&D.
Learn more
2024-01-18
To advance the development of clinical diagnostic and therapeutic techniques for companion animals in China, enhance the clinical application of canine serum albumin, and provide pet veterinarians with opportunities for learning, exchange, and professional improvement, the Chinese Veterinary Medical Association, in collaboration with Taizhou BioAlly Biotechnology Co., Ltd., plans to host the “Drip of Vitality, Revitalizing Life” – 2024 “Boshengjian Cup” Clinical Case Competition on the Application of Canine Serum Albumin. To ensure the smooth conduct of the competition, the relevant arrangements are hereby announced as follows.
Learn more
2023-11-03
Good News! China’s First Batch! BioAlly Feline Triple Vaccine Has Been Successfully Approved!
On August 23, 2023, Announcement No. 701 of the Ministry of Agriculture and Rural Affairs was issued, announcing that BioAlly’s independently developed trivalent inactivated vaccine against feline panleukopenia, feline rhinotracheitis, and feline calicivirus (strains HBX05, BJS01, and BJH13) has successfully passed the emergency evaluation conducted by the Ministry and has been approved. This milestone marks the first-ever domestically produced feline vaccine.
Learn more